Project Grant R00HD110612

Award Date 7/1/25
Completion Date 6/30/28
Dollars Obligated $761K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $148,880.00 to the University of Mississippi Medical Center to investigate the long-term effects of preeclampsia (PE) on offspring. The key research objectives are to: 1) Test the hypothesis that B cells from PE women produce autoantibodies that contribute to hypertension,...
This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 (Child Health and Human Development Extramural Research) aims to develop and evaluate water-soluble prodrugs of the novel therapeutic compound AKT-1005 for the treatment of preeclampsia. The $468,540 award to Beth Israel Deaconess Medical Center, Inc. (BIDMC) will fund research to synthesize and screen AKT-1005 prodrugs for improved solubility,...
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development provides $769,916 to Emergent Biotechnologies LLC for research into a novel therapy for preeclampsia. The funding supports Phase 1 of developing and characterizing a handle region peptide as an innovative treatment for preeclampsia under the Child Health and Human Development Extramural Research program (CFDA 93.865). Phase 1 work will...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $485,925 to the University of Massachusetts Boston to develop novel antioxidant compounds for treating preeclampsia, a life-threatening pregnancy complication. The primary goal is to design and synthesize cationic hydrazone antioxidants that can target mitochondria to reduce oxidative stress, improve...
This Project Grant award of $698,750 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to develop a targeted, placenta-tropic lipid nanoparticle (LNP) platform for delivering therapeutic mRNA cargo to the placenta to treat pre-eclampsia, a serious pregnancy condition. The key products and services to be delivered include: High-throughput screening of a large library of novel...
This $424,373 Project Grant, awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to identify and validate transcription factors that control preeclampsia-specific gene expression programs. The project will utilize human trophoblast stem cells as a model system to elucidate the regulatory mechanisms of these "preeclampsia-driver" transcription factors...
This Project Grant award of $248,999 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to identify effective therapeutic agents for managing infection-induced preterm labor (III-PTL) and protecting against fetal inflammation. The key activities under this award include: 1) Optimizing a high-throughput screening assay to measure changes in pro-inflammatory cytokines...
This Project Grant award, issued by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $219,592 in funding to the University of Nevada, Reno to develop novel designed multi-ligand (DML) drugs as potential tocolytics for the treatment of preterm labor. The key goals of this research are to generate DML drug candidates that can target dysregulated pathways in preterm myometrium to...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 Child Health and Human Development Extramural Research provides $429,000.00 to the University of Colorado-Denver for a 2-year project to develop optogenetic and chemogenetic models to regulate uterine vascular function and prevent fetal growth restriction (FGR). The key products and services to be delivered through this award include: Establishing mouse models expressing...
This $232,500 Project Grant awarded by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) to Wake Forest University Health Sciences will fund research to establish the neuroprotective actions of the apelinergic axis on the long-term cerebrovascular consequences of preeclampsia. The research aims to improve understanding of the protective role of the apelin/APJ axis in preeclampsia, a hypertensive disorder of...

This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $760,950 to support research focused on employing biologics to probe G protein-coupled receptor (GPCR) signaling in maternal and fetal health.

The key objectives are to: 1) characterize the mechanisms antibody fragments use to suppress angiotensin II type I receptor (AT1R) signaling and demonstrate their ability to selectively target maternal AT1R to safely treat hypertension during pregnancy; 2) develop antibody selection strategies to mechanistically probe how synthetic antibody fragments stabilize distinct states of AT1R and oxytocin receptor (OXTR) to regulate the recruitment of signaling effectors and direct biological responses; and 3) investigate the mechanisms by which pathogenic autoantibodies dysregulate AT1R signaling in preeclampsia. This multidisciplinary research, combining receptor pharmacology, structural biology, and antibody engineering, aims to provide insights into GPCR signaling, the pathophysiology of preeclampsia, and new therapeutic approaches for pregnancy-related complications.

Generated 8/5/25, 5:41 AM